Patent ID: 8449883

Claim:
A method of treating cancer comprising administering an antibody drug conjugate compound to a patient wherein the cancer is selected from prostate cancer, cancer of the urinary tract, pancreatic cancer, lung cancer, breast cancer, colon cancer and ovarian cancer, and the antibody drug conjugate compound comprises an antibody covalently attached by a linker to one or more toxin drug moieties, the compound having the formula: Ab-(L-D)p or a pharmaceutically acceptable salt or solvate thereof, wherein: Ab is (1) a monoclonal antibody produced by the hybridoma cell 3A5.3 that binds to a TAT10772 polypeptide, or (2) an antibody that specifically binds to a TAT10772 polypeptide, said antibody comprising three light chain hypervariable regions (HVR-L1, HVR-L2 and HVR-L3) and three heavy chain hypervariable regions (HVR-H1, HVR-H2 and HVR-H3) wherein: (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO:119; (b) HVR-L2 comprises the amino acid sequence of any one of SEQ ID NOS:120-121; (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO:122; (d) HVR-H1 comprises the amino acid sequence of SEQ ID NO:123; (e) HVR-H2 comprises the amino acid sequence of any one of SEQ ID NOS:124-127; and (f) HVR-H3 comprises the amino acid sequence of any one of SEQ ID NOS:128-183; L is a linker; D is a toxin drug moiety; and p is 1 to about 20.